Updates are available Correction dated 2025-07-21

Article History

Received: 2 October 2024

Accepted: 11 March 2025

First Online: 20 March 2025

Change Date: 21 July 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s42358-025-00466-3

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that the research was carried out in the absence of any commercial or financial relationship that could be interpreted as a potential conflict of interest. Several authors of these guidelines, including voting members, have interacted with the pharmaceutical industry including the manufacturers of some of the drugs mentioned in these recommendations. However, none of the authors received any support or fee directly or indirectly related to or influencing the development of these guidelines. AKGM received speaker fees and consulting from Abbvie, Johnson & Johnson. AMK received consuting fees from Abbvie, Lilly, UCB, Organon, and Janssen. CF received speaker fees from Takeda, Janssen, Abbvie, Amgen, Organon. ESP received speaker fees and consulting from Abbvie, Novartis, Lilly, Johnson & Johnson. JSC received speaker fees from GSK and Janssen. KLLLM received speaker fees and consulting from Novartis and Johnson & Johnson. LAC received speaker fees and consulting from Johnson & Johnson, Takeda, Abbvie. LDAV received speaker fees and consulting from Novartis, Johnson & Johnson. LMHM received speaker fees and consulting from Johnson & Johnson, Abbvie, Pfizer, Novartis, Amgen, Organon, Celltrion, UCB. MFBRG received speaker fees and consulting from Johnson & Johnson, Abbvie, Amgen, Lilly, UCB. MIBFL received speaker fees and consulting from Abbvie, Novartis, Takeda, Johnson & Johnson. MMP received consuting fees from Abbvie, Lilly and Janssen. RMX received Speaker fees, consulting, research funding from Abbvie, Pfizer, Amgen, Biogen, Novartis, Janssen, UCB. RR is/has served as a scientific consultant, speaker, or clinical study investigator for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Janssen-Cilag, Eli-Lilly, Leo-Pharma, Novartis, Pfizer, Sanofi, and UCB. RSH received speaker fees and consulting from Abbvie, Novartis, Takeda, Johnson & Johnson. OAM received consulting fees from AstraZeneca and GSK; received payment or honoraria for lectures or presentations from AbbVie, Janssen, GSK, UCB and AstraZeneca; and participated in a data safety monitoring board or advisory board for GSK, CellTrion, Bristol, Novartis, Janssen, and AstraZeneca. VAS received speaker fees and consulting from Abbvie, Novartis, Lilly, Johnson & Johnson, GSK, Astrazeneca. VFA received speaker fees, consulting, clinical researches from Celltiron, Amgen, Janssen, Organon, Sandoz, Abbvie, Fresenius Kabi, Takeda, LG, Boehringer-Ingelheim, Bristol Myers-Squibb, GSK, AstraZeneca. Eduardo dos Santos Paiva is Co-EiC of Advances in Rheumatology. Ana Karla Guedes de Melo, Ana Cristina de Medeiros Ribeiro and Marcelo de Medeiros Pinheiro are Associate Editors of the journal Advances in Rheumatology; Ricardo Machado Xavier is a Consulting editor of the journal; Adriana Maria Kakehasi and Licia Maria Henrique da Mota are members of the editorial board of this journal. The peer-review of this paper was therefore overseen by an independent member of the editorial board while the submission was subject to the exact same review process as applied to any other manuscript. The authors not mentioned above declare no competing interests.